Share
5 min read
researchEvidence-based

Conference Analysis: Two FDA-approved tau scans disagree 47% of the time. One is right.

Always be sure to check which tracers they are using for you tau PET scans

T
· Reviewed by Dr. Kevin Tran, PharmD

Key takeaways · TL;DR

Two FDA-approved tau PET tracers, MK-6240 and Flortaucipir, disagree 47 percent of the time, with MK-6240 detecting tau roughly 20 to 30 centiloids (3 to 5 years) earlier. Pharmaceutical companies now use MK-6240 exclusively for Alzheimer trials. APOE4 carriers considering tau PET scans should ask which tracer their facility uses.

Definition

A tau PET tracer with higher sensitivity that detects Alzheimer-related tau roughly 3 to 5 years earlier than Flortaucipir.

Pharmaceutical companies now use MK-6240 exclusively for Alzheimer clinical trials due to its earlier detection window, making it the preferred choice for APOE4 carriers seeking early pathology screening.

Definition

Fluid-filled channels around brain blood vessels that serve as pathways for the glymphatic waste clearance system.

Enlarged perivascular spaces on MRI indicate impaired drainage of amyloid and tau, and can appear years before cognitive symptoms. The DOORS tool detects them with 96 percent accuracy.

MK-6240 vs Flortaucipir Tau PET Tracers

TracerEarly detection advantageClinical trial use
MK-6240Detects tau 20-30 centiloids (3-5 years) earlierUsed exclusively by pharma
FlortaucipirLess sensitive early in diseaseLargely phased out of trials

Just analyzed six presentations from the Imaging in Neurodegenerative Diseases conference. The findings completely change how we understand Alzheimer's detection:

The Data

- "Concordance is only 47% between tracers" - Dr. Andreia Rocha on MK-6240 vs Flortaucipir

- "MK is always one step ahead" - detecting tau 20-30 centiloids (3-5 years) earlier

- "Cortical thickness may increase in early stages" - Dr. Ting Qiu's 10-year study showing biphasic pattern

Why This Matters:

1. If you're getting tau PET, the tracer choice determines whether problems are caught

2. Brain enlargement before shrinkage = missed intervention window

3. Pharmaceutical companies have already chosen MK-6240 for trials

The Brain Drainage Discovery:

Dr. James LeFevre (Vanderbilt) presented DOORS tool - 96% accurate at detecting enlarged perivascular spaces (failed brain waste clearance) years before symptoms.

Action Items:

- Ask which tau tracer if getting PET scan

- P-tau217 blood test available ($300-400)

- Standard MRI can show drainage problems

The video covers:

- All six presentations analyzed

- Why scans disagree (different tau conformations)

- Three distinct Alzheimer's patterns

- What this means for early detection

Thoughts on the biphasic brain volume pattern? Anyone else surprised by the scan disagreement rate?

Edit: Industry consultant at conference confirmed pharma companies are using MK-6240 exclusively for trials now.

Filed under
researchtrackingcognition

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

FAQ

Frequently asked questions.

Why do two FDA-approved tau PET scans disagree?
Dr. Andreia Rocha reported that MK-6240 and Flortaucipir show only 47 percent concordance. The disagreement comes from differences in how each tracer binds to tau. Different conformations of the tau protein are detected with different sensitivity by each tracer, so the same patient can appear tau positive on one scan and tau negative on the other. This has major implications for how APOE4 carriers interpret results and which tracer their imaging center uses.
Which tau tracer detects Alzheimer disease earlier?
MK-6240 appears to be one step ahead of Flortaucipir, detecting tau roughly 20 to 30 centiloids (about 3 to 5 years) earlier in the disease process. Because pharmaceutical companies are now using MK-6240 exclusively for Alzheimer trials, the clinical research world has essentially voted with its feet. For APOE4 carriers who want the earliest possible intervention window, asking for MK-6240 tau PET imaging is a concrete, actionable step.
What is the biphasic brain volume pattern in Alzheimer disease?
Dr. Ting Qius 10-year study revealed that cortical thickness may actually increase in the early stages of Alzheimer disease before later shrinkage. This biphasic pattern means that relying on brain atrophy as an early warning sign misses a critical intervention window. Early disease may present as brain enlargement due to inflammation or compensatory processes, then transition to atrophy. For APOE4 carriers, this underscores the importance of multimodal detection rather than relying on MRI volume alone.
What is the DOORS tool and what does it detect?
DOORS is a tool presented by Dr. James LeFevre at Vanderbilt that is 96 percent accurate at detecting enlarged perivascular spaces on standard MRI. Enlarged perivascular spaces indicate failed brain waste clearance, meaning the glymphatic system that should flush amyloid and tau is not working properly. DOORS can identify this drainage problem years before symptoms appear, giving APOE4 carriers another early warning signal that does not require expensive PET imaging, only a standard MRI that can be reanalyzed with the tool.
How much does a p-tau217 blood test cost?
The p-tau217 blood test is available for roughly 300 to 400 dollars. It is one of the most promising blood-based biomarkers for early Alzheimer detection and offers a far lower cost and more accessible alternative to PET imaging. For APOE4 carriers who want to track tau-related risk without a PET scan, p-tau217 combined with a standard MRI can provide useful early signals at a fraction of the cost of advanced imaging.
Keep reading

Related protocols.